We created a model to estimate the total medication costs of treating patients with rheumatoid arthritis with 6 second-line agents for the first 6 months of treatment.
Drug costs were obtained from a survey of pharmacies ; monitoring costs were calculated from utilization information obtained in a survey of rheumatologists ; toxicity costs were obtained using decision trees to represent the evaluation and treatment of potential toxicities.
The least expensive medication was penicillamine, at $10.62/week, and the most expensive was injectable gold, at $30.89/week.
In terms of monitoring costs, methotrexate had the highest costs associated with necessary laboratory tests and office visits.
Hematologic toxicities were the largest component of toxicity costs for all 6 medications, and renal toxicities were costly for patients taking oral gold, penicillamine, and injectable gold.
Total medication costs revealed oral gold as the least expensive medication and injectable gold as the most expensive.
The combination of monitoring and toxicity costs accounted for more than 60% of the total costs for all medications except injectable gold.
In all cases, the cost of treating toxicities was the smallest of the 3 components.
When calculating the costs of drug therapy, it is important to consider not only the price of the drug, but also the costs of monitoring and treating the toxicities that might occur.
Mots-clés Pascal : Polyarthrite rhumatoïde, Homme, Etats Unis, Evaluation, Economie santé, Analyse coût, Modèle, Traitement, Chimiothérapie, Etude comparative, Médicament, Antirhumatismal, Antiinflammatoire, Chronique, Amérique du Nord, Amérique, Système ostéoarticulaire pathologie, Rhumatisme inflammatoire, Immunopathologie, Maladie autoimmune
Mots-clés Pascal anglais : Rheumatoid arthritis, Human, United States, Evaluation, Health economy, Cost analysis, Models, Treatment, Chemotherapy, Comparative study, Drug, Antirheumatic agent, Antiinflammatory agent, Chronic, North America, America, Diseases of the osteoarticular system, Inflammatory joint disease, Immunopathology, Autoimmune disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0287752
Code Inist : 002B30A01C. Création : 01/03/1996.